Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zhejiang Zheda Insigma Group is a China-based information technology and digitalization company best known as Insigma/浙大网新, rather than a drug-development biotech or pharmaceutical company. The group provides IT consulting, cloud, AI, smart-city, public-sector, and industry digitalization services, including healthcare and medical-insurance informatics solutions. Its healthcare-related activities appear to be concentrated in digital health, smart medical services, medical insurance systems, mobile medical payment, and healthcare data platforms rather than therapeutics, diagnostics pipelines, or regulated drug products. The company is publicly traded in Shanghai and operates across multiple digital infrastructure and software service lines. For a biotech analyst, the key point is that this is primarily a healthcare-adjacent technology vendor, not a life sciences therapeutics company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zhejiang Zheda Insigma Group.